NEW BRUNSWICK, N.J. - Johnson & Johnson (NYSE: JNJ) has entered into a definitive agreement to acquire the global rights to NM26, a Phase 2-ready investigational bispecific antibody for atopic dermatitis (AD), from Numab Therapeutics. The transaction, valued at approximately $1.25 billion, is expected to close in the second half of 2024, subject to customary closing conditions and regulatory approvals.
NM26 targets two clinically proven pathways associated with AD, the IL-4R alpha subunit and IL-31, which are involved in skin inflammation and itching. The acquisition is part of Johnson & Johnson's commitment to developing therapies that address unmet needs in immune-mediated diseases by targeting multiple disease pathways.
David Lee, Global Immunology Therapeutic Area Head at Johnson & Johnson Innovative Medicine, stated that NM26 is designed to offer a specific treatment for AD patients suffering from inflamed skin and intense itching. Current treatments often fail to provide durable, symptom-free remission, with a significant portion of patients not achieving remission from this common inflammatory skin disease.
Candice Long, Worldwide Vice President of Immunology at Johnson & Johnson, emphasized the company's goal to deliver transformational efficacy for patients with AD and other immune-mediated diseases. The investment in bispecific antibodies is seen as a continuation of Johnson & Johnson's legacy in immunology and its strategy to meet medical needs by leveraging patient insights and disease expertise.
The press release cautions that forward-looking statements regarding the acquisition should not be overly relied upon, as actual results could differ due to various risks and uncertainties. These include challenges in product development, regulatory approvals, commercial success, and potential economic and competitive pressures.
This news is based on a press release statement from Johnson & Johnson and does not include any marketing promotion or speculative commentary. The information provided is intended to offer a factual update on the company's strategic move to expand its portfolio in the field of immunology and innovative medicine.
InvestingPro Insights
As Johnson & Johnson (NYSE: JNJ) takes strategic steps to enhance its immunology portfolio through the acquisition of NM26, it's important for investors to consider the financial health and market position of the company.
With a solid market capitalization of $353.71 billion and a P/E ratio that stands at 9.49, Johnson & Johnson is showcasing its financial stability in the market. This is further evidenced by the company's robust revenue growth over the last twelve months as of Q1 2024, which is reported at 10.57%.
Investors may find confidence in Johnson & Johnson's commitment to shareholder value, as indicated by two notable InvestingPro Tips: the company has not only raised its dividend for 53 consecutive years but has also maintained these payments for 54 consecutive years, reflecting a strong and consistent return to shareholders. Moreover, the stock generally trades with low price volatility, suggesting a lower risk profile for investment.
With analysts predicting profitability for the year and the company trading near its 52-week low, there could be potential for upside. The dividend yield as of the given date stands at 3.37%, which is competitive in the current market environment. These insights, among others, can be further explored with additional InvestingPro Tips available on InvestingPro. For those interested in a deeper dive, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, and access the full suite of 10 additional InvestingPro Tips that can help inform your investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.